tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Milestone Pharmaceuticals: Undervalued CARDAMYST Opportunity with EU Upside and Strong Risk‑Reward Supporting Buy Rating
PremiumRatingsMilestone Pharmaceuticals: Undervalued CARDAMYST Opportunity with EU Upside and Strong Risk‑Reward Supporting Buy Rating
1M ago
Milestone’s PSVT nasal spray MAA accepted by EMA
Premium
Company Announcements
Milestone’s PSVT nasal spray MAA accepted by EMA
1M ago
Milestone announces acceptance of MAA by EMA for etripamil nasal spray
Premium
The Fly
Milestone announces acceptance of MAA by EMA for etripamil nasal spray
1M ago
Milestone Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright
PremiumThe FlyMilestone Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright
2M ago
Milestone Pharmaceuticals Gains FDA Approval for CARDAMYST
Premium
Company Announcements
Milestone Pharmaceuticals Gains FDA Approval for CARDAMYST
2M ago
Milestone Pharmaceuticals receives FDA approval of CARDAMYST
Premium
The Fly
Milestone Pharmaceuticals receives FDA approval of CARDAMYST
2M ago
Milestone Pharmaceuticals: Positioned for Success with Cardamyst’s Potential Approval and Launch
PremiumRatingsMilestone Pharmaceuticals: Positioned for Success with Cardamyst’s Potential Approval and Launch
3M ago
Milestone Pharmaceuticals reports Q3 EPS (12c), consensus (17c)
Premium
The Fly
Milestone Pharmaceuticals reports Q3 EPS (12c), consensus (17c)
3M ago
MIST Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
MIST Earnings this Week: How Will it Perform?
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100